SCHEMBL1874142

SCHEMBL1874142

Cc1cccc(-c2noc(N)c2-c2ccncn2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.61
MAPK9 P45984 1/20 0.61
MAPK10 P53779 1/20 0.61
MAPK11 Q15759 1/20 0.61
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HTR7 P34969 1/20 0.40
GRM5 P41594 1/20 0.40
BRD4 O60885 2/20 0.39
TDO2 P48775 1/20 0.39
MAP4K4 O95819 2/20 0.39
ABL1 P00519 2/20 0.39
CHEK1 O14757 1/20 0.39
NTRK1 P04629 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39
MET P08581 1/20 0.39
PDGFRB P09619 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880417 0.88 MAPK14 (0.65) MAPK14MAPK9MAPK10MAPK11NPC1
SCHEMBL1880334 0.85 MAPK14 (0.61) MAPK14MAPK9MAPK10MAPK11NPC1
SCHEMBL1879874 0.85 MAPK14 (0.61) MAPK14MAPK9MAPK10MAPK11NPC1
SCHEMBL1878815 0.85 MAPK14 (0.72) MAPK14MAPK9MAPK10MAPK11HTR7
SCHEMBL1876992 0.84 MAPK11 (0.57) MAPK14MAPK9MAPK10MAPK11NPC1
SCHEMBL1876030 0.84 MAPK14 (0.75) MAPK14MAPK9MAPK10MAPK11NPC1
SCHEMBL4338473 0.84 MAPK14 (0.57) MAPK14MAPK11NPC1RAB9AHTR7
SCHEMBL1878049 0.84 MAPK14 (0.74) MAPK14MAPK9MAPK10MAPK11BRD4
SCHEMBL1871452 0.83 MAPK14 (0.66) MAPK14MAPK9MAPK10MAPK11NPC1
SCHEMBL1874520 0.82 MAPK14 (0.60) MAPK14MAPK9MAPK10MAPK11BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.